EXCLUSIVE: Lineage Cell Therapeutics Tells Benzinga It Has Development Activities For Hypoimmune Pluripotent Cell Line For Neurology Indications Under Co.'s Partnership With Eterna Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Lineage Cell Therapeutics has announced that it is developing a hypoimmune pluripotent cell line for neurology indications under its partnership with Eterna Therapeutics.
September 06, 2023 | 11:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eterna Therapeutics is partnering with Lineage Cell Therapeutics on the development of a new product, which could potentially increase its market share and revenues.
The partnership with Lineage Cell Therapeutics on the development of a new product could potentially increase Eterna Therapeutics' market share and revenues. This is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Lineage Cell Therapeutics is developing a new product, which could potentially increase its market share and revenues.
The development of a new product could potentially increase Lineage Cell Therapeutics' market share and revenues. This is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100